Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy

Parkinsonism and Related Disorders

Volumn 21, Issue 6, 2015, Pages 567-572

  Goldstein, David S ^a   Sullivan, Patricia ^a   Holmes, Courtney ^a   Kopin, Irwin J ^a   Sharabi, Yehonatan ^b   Mash, Deborah C ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

DOPAL; Dopamine; Multiple system atrophy; Norepinephrine; Parkinson disease; Putamen

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ACETALDEHYDE; ALDEHYDE DEHYDROGENASE; DOPAMINE; LEVODOPA; NORADRENALIN; UNCLASSIFIED DRUG; 3,4-DIHYDROXYPHENYLACETALDEHYDE; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DOPA;

ADULT; AGED; ARTICLE; CATECHOLAMINE METABOLISM; CAUDATE NUCLEUS; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; LOCUS CERULEUS; NERVE CELL NECROSIS; NEUROCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SHY DRAGER SYNDROME; ANALOGS AND DERIVATIVES; FRONTAL LOBE; MALE; METABOLISM; NERVE CELL; VERY ELDERLY;

3,4-DIHYDROXYPHENYLACETIC ACID; AGED; AGED, 80 AND OVER; ALDEHYDE DEHYDROGENASE; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FRONTAL LOBE; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MULTIPLE SYSTEM ATROPHY; NEURONS; NOREPINEPHRINE; PARKINSON DISEASE;

EID: 84929506145     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.03.006     Document Type: Article

References (28)

1. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998, 44:415-422.
2. Wakabayashi K., Yoshimoto M., Tsuji S., Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998, 249:180-182.
3. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
4. Tong J., Wong H., Guttman M., Ang L.C., Forno L.S., Shimadzu M., et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 2010, 133:172-188.
5. Rajput A.H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991, 18:275-278.
6. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
7. Joutsa J., Gardberg M., Roytta M., Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 2014, 20:840-844.
8. Litvan I., Goetz C.G., Jankovic J., Wenning G.K., Booth V., Bartko J.J., et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997, 54:937-944.
9. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988, 318:876-880.
10. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431.
11. DelleDonne A., Klos K.J., Fujishiro H., Ahmed Z., Parisi J.E., Josephs K.A., et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008, 65:1074-1080.
12. Goldstein D.S., Sullivan P., Holmes C., Miller G.W., Alter S., Strong R., et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem 2013, 126:591-603.
13. Goldstein D.S., Sullivan P., Holmes C., Miller G.W., Sharabi Y., Kopin I.J. A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease. J Neurochem 2014 May 22, [Epub ahead of print]. 10.1111/jnc.12766.
14. Goldstein D.S., Holmes C., Kopin I.J., Sharabi Y. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Inv 2011, 121:3320-3330.
15. Rees J.N., Florang V.R., Eckert L.L., Doorn J.A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem Res Toxicol 2009, 22:1256-1263.
16. Anderson D.G., Mariappan S.V., Buettner G.R., Doorn J.A. Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J Biol Chem 2011, 286:26978-26986.
17. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011, 108:4194-4199.
18. Burke W.J., Kumar V.B., Pandey N., Panneton W.M., Gan Q., Franko M.W., et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008, 115:193-203.
19. Jinsmaa Y., Sullivan P., Gross D., Cooney A., Sharabi Y., Goldstein D.S. Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neurosci Lett 2014, 569:27-32.
20. Goldstein D.S., Kopin I.J., Sharabi Y. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther 2014.
21. Williams S.M., Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998, 8:321-345.
22. Devoto P., Flore G., Longu G., Pira L., Gessa G.L. Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse 2003, 50:200-205.
23. Holmes C., Eisenhofer G., Goldstein D.S. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994, 653:131-138.
24. Goldstein D.S., Holmes C., Bentho O., Sato T., Moak J., Sharabi Y., et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008, 14:600-607.
25. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 2008, 11:755-761.
26. Wilk S., Stanley M. Dopamine metabolites in human brain. Psychopharmacology (Berl) 1978, 57:77-81.
27. Goldstein D.S., Holmes C., Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 2012, 135:1900-1913.
28. Eldrup E., Mogensen P., Jacobsen J., Pakkenberg H., Christensen N.J. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Acta Neurol Scand 1995, 92:116-121.